Boston Trust Walden Corp Acquires 9,474 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Boston Trust Walden increased its Regeneron stake 794.1% in the third quarter, buying 9,474 shares to reach 10,667 shares valued at about $8.1 million.
• Regeneron reported quarterly EPS of $20.07, above the $16.51 consensus, and revenue of $5.12 billion, up 36.3% year over year.
• Company insiders sold 28,228 shares worth approximately $26.0 million in the last quarter. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $898.97.

Boston Trust Walden Corp increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 794.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,667 shares of the biopharmaceutical company's stock after purchasing an additional 9,474 shares during the period. Boston Trust Walden Corp's holdings in Regeneron Pharmaceuticals were worth $8,088,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $26,000. Armstrong Advisory Group Inc. grew its stake in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 28 shares during the period. Activest Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 39 shares in the last quarter. Alpine Bank Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, insider Andrew J. Murphy sold 4,147 shares of the company's stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares of the company's stock, valued at $36,960,559.10. This represents a 7.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph J. Larosa sold 4,466 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the transaction, the executive vice president owned 38,906 shares of the company's stock, valued at $37,563,353.94. The trade was a 10.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 28,228 shares of company stock valued at $25,985,950 in the last quarter. Insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ:REGN opened at $904.35 on Friday. The company has a market capitalization of $93.11 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 1.51 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. The business has a fifty day moving average price of $804.38 and a two-hundred day moving average price of $742.81. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts' consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion for the quarter, compared to analysts' expectations of $4.58 billion. During the same period in the previous year, the business posted $11.83 EPS. The business's revenue for the quarter was up 36.3% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.30%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on REGN shares. Robert W. Baird lifted their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a "neutral" rating in a report on Monday, November 2nd. UBS Group raised shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the company from $660.00 to $978.00 in a research report on Thursday, October 15th. Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the stock a "market perform" rating in a report on Monday, November 2nd. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a "buy" rating in a report on Wednesday, October 21st. Finally, Argus raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $850.00 price objective for the company in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $898.97.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company's medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.